Evidence-led CBD education for UK readers
A pre-appointment briefing for UK readers who use CBD oils, capsules or vapes and have dental treatment planned under local anaesthetic. It sets out why disclosure is worth the small effort, what the pharmacological literature does and does not support, and how to prepare a short, useful note for your dentist.
A 500mg balm and a 500mg dropper are not the same proposition, and the number on the front of the jar does not tell you what reaches the bloodstream. This explainer looks at how UK cosmetic and medicinal claims differ, why concentration and delivered dose diverge, and what a sensible patch test and label read should actually cover.
Cannabidiol is not on the WADA prohibited list, but that does not make every high-street CBD product safe for a tested athlete. This locker-side guide sets out what to check — batch data, route of administration, records — before a competition, and why 'THC-free' on a label is not a guarantee.
A product sold openly in another country can still raise UK-specific questions about novel food status, THC limits, labelling and claims. This second-look checklist is for UK readers who want to look past global branding and foreign lab reports before buying imported CBD.
Many UK readers ask whether CBD can affect hormonal contraception. The honest answer is that direct human evidence is limited, while a theoretical interaction is plausible enough to discuss with a pharmacist or GP. This guide separates what is known from what remains uncertain.
The office Christmas do can mix late nights, alcohol and hopeful experimentation with CBD. This harm-reduction guide explains what is known about combining CBD with drinking, how to read dose and quality labels, and when to ask a pharmacist before the party.
CBD products aimed at perimenopause and menopause now appear on more UK shelves, often wrapped in ‘hormone-friendly’ language. This audit separates what the evidence can support from what the marketing implies, and sets out the questions to ask about quality, interactions and GP advice.
For UK drivers, the question is not whether CBD is legal to buy but whether a product could affect a roadside test, impair judgement or interact with other medicines. This doctor-informed guide sets out the questions to ask before driving after using CBD, without offering legal advice.
'Start low, go slow' is memorable, but it can flatter poor product information and obscure the fact that CBD concentration, carrier oil and batch consistency vary widely. This evidence-led opinion piece explains titration in plain language and offers a simple diary method for asking better questions.
The entourage effect is the central sales argument for full-spectrum and broad-spectrum CBD, and the justification for much of the price premium attached to them. This analysis examines what the theory proposes, how limited the human evidence remains, and how UK labels deploy the term.
Raising CBD in a GP appointment is neither a confession nor a request for permission. This guide sets out how to describe what you are taking, why the interaction question matters more than the marketing, and what UK prescribing and food-safety guidance can realistically offer in a short consultation.
Phrases such as doctor-formulated, clinically studied and pharmacist-approved can sound authoritative, but their meaning in UK CBD marketing is often narrower than readers assume. This opinion-led guide offers a practical framework for judging health claims, conflicts of interest and whether a site actually cites credible evidence.
A Novel Foods listing is a useful starting point, but it is not proof of potency, purity or clinical benefit. This buyer-education checklist explains how UK readers can trace a CBD product to a batch, read a laboratory report and ask sharper questions before buying.